Safety and pharmacokinetics of paclitaxel and the oral mTOR inhibitor everolimus in advanced solid tumours

British Journal of Cancer

Volumn 100, Issue 2, 2009, Pages 315-321

  Campone, M ^a   Levy, V ^b   Bourbouloux, E ^a   Berton Rigaud, D ^a   Bootle, D ^c   Dutreix, C ^c   Zoellner, U ^c   Shand, N ^c   Calvo, F ^b   Raymond, E ^b,d  

^a CENTRE RENÉ GAUDUCHEAU   (France)

^b SAINT LOUIS HOSPITAL   (France)

^c NOVARTIS PHARMA AG   (Switzerland)

^d BEAUJON HOSPITAL   (France)

Author keywords

Combination chemotherapy; Drug interaction; Everolimus; Paclitaxel; Phase I; RAD001

Indexed keywords

CORTICOSTEROID; EVEROLIMUS; FLUCONAZOLE; GRANISETRON; ONDANSETRON; PACLITAXEL; STEROID; TAXANE DERIVATIVE;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALLERGIC REACTION; ALOPECIA; ANEMIA; ANGIOSARCOMA; ARTHRALGIA; ARTICLE; ASTHENIA; BREAST CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG SAFETY; DRUG WITHDRAWAL; ERYSIPELAS; ERYTHEMA; FEMALE; FEVER; HEADACHE; HUMAN; INTERSTITIAL PNEUMONIA; LEUKOPENIA; MALE; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUTROPENIA; OVARY CANCER; PARESTHESIA; PRIORITY JOURNAL; PRURITUS; SIDE EFFECT; SKIN DEFECT; SOLID TUMOR; STOMATITIS; THROMBOCYTOPENIA; VAGINA CANCER; VOMITING;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS; PACLITAXEL; PROGNOSIS; PROTEIN KINASES; SIROLIMUS; SURVIVAL RATE; TISSUE DISTRIBUTION; TREATMENT OUTCOME;

EID: 58749107489     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6604851     Document Type: Article

References (44)

1. Aissat N, Le Tourneau C, Ghoul A, Serova M, Bieche I, Lokiec F, Raymond E, Faivre S (2007) Antiproliferative effects of rapamycin as a single agent and in combination with carboplatin and paclitaxel in head and neck cancer cell lines. Cancer Chemother Pharmacol 62: 305-313
2. André F, Campone M, Hurvitz SA, Vittori L, Pylvaenaeinen I, Sahmoud T, O'Regaan RM (2008) Muticenter phase I clinical trial of daily and week RAD001 (everolimus) in combination with weekly paclitaxel and trastuzumab in patients with HER-2-overexpressing metastatic breast cancer with prior resistance to trastuzumab. J Clin Oncol 26(Suppl): 41s (Abstract 1003)
3. Bacus SS, Altomare DA, Lyass L, Chin DM, Farrell MP, Gurova K, Gudkov A, Testa JR (2002) AKT2 is frequently upregulated in HER-2/neu-positive breast cancers and may contribute to tumor aggressiveness by enhancing cell survival. Oncogene 21: 3532-3540
4. Beuvink I, O'Reilly T, Zumstein S (2001) Antitumor activity of RAD001, an orally active rapamycin derivative. Proc Am Assoc Cancer Res 42: 366 (Abstract 1972)
5. Boulay A, Zumstein-Mecker S, Stephan C, Beuvink I, Zilbermann F, Haller R, Tobler S, Heusser C, O'Reilly T, Stolz B, Marti A, Thomas G, Lane HA (2004) Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells. Cancer Res 64: 252-261
6. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, Wolter JM, Paton V, Shak S, Lieberman G, Slamon DJ (1999) Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17: 2639-2648
7. David O, Jett J, LeBeau H, Dy G, Hughes J, Friedman M, Brody AR (2004) Phospho-Akt overexpression in non-small cell lung cancer confers significant stage-independent survival disadvantage. Clin Cancer Res 10: 6865-6871
8. El-Maraghi RH, Ellard S, Gelmon K, Mckintosh L, Seymour L (2006) Pulmonary adverse events in a randomised phase II study of the mTOR inhibitor RAD001C (everolimus): NCIC CTG IND.163. Eur J Cancer Suppl 4: 164 (Abstract 541)
9. Faivre S, Kroemer G, Raymond E (2006) Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Disc 5: 671-688
10. Faried LS, Faried A, Kanuma T, Nakazato T, Tamura T, Kuwano H, Minegishi T (2006) Inhibition of the mammalian target of rapamycin (mTOR) by rapamycin increases chemosensitivity of CaSki cells to paclitaxel. Eur J Cancer 42: 934-947
11. Georgakis GV, Younes A (2006) From Rapa Nui to rapamycin: targeting PI3K/Akt/mTOR for cancer therapy. Expert Rev Anticancer Ther 6: 131-140
12. Green MC, Buzdar AU, Smith T, Ibrahim NK, Valero V, Rosales MF, Cristofanilli M, Booser DJ, Pusztai L, Rivera E, Theriault RL, Carter C, Frye D, Hunt KK, Symmans WF, Strom EA, Sahin AA, Sikov W, Hortobagyi GN (2005) Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 week. J Clin Oncol 23: 5983-5992
13. Haritunians T, Mori A, O'Kelly J, Luong QT, Giles FJ, Koeffler HP (2007) Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphoma. Leukemia 21: 333-339
14. Hu L, Hofmann J, Lu Y, Lu Y, Mills GB, Jaffe RB (2002) Inhibition of phosphatidylinositol 3′-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. Cancer Res 62: 1087-1092
15. Hu L, Zaloudek C, Mills GB, Gray J, Jaffe RB (2000) In vivo and in vitro ovarian cancer growth inhibition by a phosphatidylinositol 3-kinase inhibitor (LY294002). Clin Cancer Res 6: 880-886
16. Lane HA, Boulay B, Hattenberger M (2003) The orally active rapamycin derivative RAD001 has potential as an antitumor agent with a broad antiproliferative activity: PTEN as a molecular determinant of response. Proc Am Assoc Cancer Res 44: 314. Abstract 1608
17. Le T, Hopkins L, Baines KA, Rambout L, Al Hayki M, Kee Fung MF (2006) Prospective evaluations of continuous weekly paclitaxel regimen in recurrent platinum-resistant epithelial ovarian cancer. Gynecol Oncol 102: 49-53
18. Le XF, Hittelman WN, Liu J, McWatters A, Li C, Mills GB, Bast Jr RC (2003) Paclitaxel induces inactivation of p70 S6 kinase and phosphorylation of Thr421 and Ser424 via multiple signaling pathways in mitosis. Oncogene 22: 484-497
19. Lee S, Yang W, Lan KH, Sellappan S, Klos K, Hortobagyi G, Hung MC, Yu D (2002) Enhanced sensitization to taxol-induced apoptosis by herceptin pretreatment in ErbB2-overexpressing breast cancer cells. Cancer Res 62: 5703-5710
20. Magné N, Fischel JL, Dubreuil A, Formento P, Poupon MF, Laurent-Puig P, Milano G (2002) Influence of epidermal growth factor receptor (EGFR), p53 and intrinsic MAP kinase pathway status of tumour cells on the antiproliferative effect of ZD1839 ('Iressa'). Br J Cancer 86: 1518-1523
21. Mondesire WH, Jian W, Zhang H, Ensor J, Hung MC, Mills GB, Meric-Bernstam F (2004) Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells. Clin Cancer Res 10: 7031-7042
22. Mori K, Kamiyama Y, Kondo T, Kano Y, Kodama T (2007) Phase II study of weekly chemotherapy with paclitaxel and gemcitabine as second-line treatment for advanced non-small cell lung cancer after treatment with platinum-based chemotherapy. Cancer Chemother Pharmacol 60: 189-195
23. O'Donnell A, Faivre S, Burris III HA, Rea D, Papadimitrakopoulou V, Shand N, Lane HA, Hazell K, Zoellner U, Kovarik JM, Brock C, Jones S, Raymond E, Judson I (2008) Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J Clin Oncol 26: 1588-1595
24. O'Reilly T, Muller M, Hattenberger M, Vaxelaire J, Lane HA (2003) Antitumor activity of RAD001 in combination with cytotoxic agents. Proc Am Assoc Cancer Res 44: 136. Abstract 713
25. Pacey S, Rea D, Steven N, Brock C, Knowlton N, Shand N, Hazell K, Zoellner U, O'Donnell A, Judson I (2004) Results of a phase I clinical trial investigating a combination of the oral mTOR-inhibitor everolimus (RAD001) and gemcitabine in patients with advance cancers. J Clin Oncol 22(Suppl): 224s. Abstract 3120
26. Perez EA, Suman VJ, Rowland KM, Ingle JN, Salim M, Loprinzi CL, Flynn PJ, Mailliard JA, Kardinal CG, Krook JE, Thrower AR, Visscher DW, Jenkins RB (2005) Two concurrent phase II trials of paclitaxel/carboplatin/trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing metastatic breast cancer: NCCTG study 983252. Clin Breast Cancer 6: 425-432
27. Perez-Tenorio G, Stal O, Southeast Sweden Breast Cancer Group (2002) Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients. Br J Cancer 86: 540-545
28. Pham PT, Pham PC, Danovitch GM, Ross DJ, Gritsch HA, Kendrick EA, Singer J, Shah T, Wilkinson AH (2004) Sirolimus-associated toxicity. Transplantation 77: 1215-1220
29. Punt CJ, Boni J, Bruntsch U, Peters M, Thielert C (2003) Phase I and pharmacokinetic study of CCI-779, a novel cytostatic cell-cycle inhibitor, in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumors. Ann Oncol 14: 931-937
30. Ramalingam S, Barstis J, Perry MC, La Rocca RV, Nattam SR, Rinaldi D, Clark R, Mills GM, Belani CP (2006) Treatment of elderly non-small cell lung cancer patients with three different schedules of weekly paclitaxel in combination with carboplatin: subanalysis of a randomized trial. J Thorac Oncol 1: 240-244
31. Saal LH, Holm K, Maurer M, Memeo L, Su T, Wang X, Yu JS, Malmström PO, Mansukhani M, Enoksson J, Hibshoosh H, Borg A, Parsons R (2005) PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast cancer. Cancer Res 65: 2554-2559
32. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, Yan H, Gazdar A, Powell SM, Riggins GJ, Willson JK, Markowitz S, Kinzler KW, Vogelstein B, Velculescu VE (2004) High frequency of mutations of the PIK3CA gene in human cancers. Science 304: 554
33. Schuette W, Blankenburg T, Guschall W, Dittrich I, Schroeder M, Schweisfurth H, Chemaissani A, Schumann C, Dickgreber N, Appel T, Ukena D (2006) Multicenter randomized trial for stage IIIB/IV non-small-cell lung cancer using every-3-week versus weekly paclitaxel/ carboplatin. Clin Lung Cancer 7: 338-343
34. Shayesteh L, Lu Y, Kuo WL, Baldocchi R, Godfrey T, Collins C, Pinkel D, Powell B, Mills GB, Gray JW (1999) PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet 21: 99-102
35. Stathopoulos GP, Malamos NA, Aravantinos G, Rigatos S, Christodoulou Ch, Stathopoulos J, Skarlos D (2007) Weekly administration of topotecan-paclitaxel as second-line treatment in ovarian cancer. Cancer Chemother Pharmacol 60: 123-128
36. Tabernero J, Rojo F, Calvo E, Burris H, Judson I, Hazell K, Martinelli E, Ramon y Cajal S, Jones S, Vidal L, Shand N, Macarulla T, Ramos FJ, Dimitrijevic S, Zoellner U, Tang P, Stumm M, Lane HA, Lebwohl D, Baselga J (2008) Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors. J Clin Oncol 26: 1603-1610
37. Tanaka C, O'Reilly T, Kovarik JM, Shand N, Hazell K, Judson I, Raymond E, Zumstein-Mecker S, Stephan C, Boulay A, Hattenberger M, Thomas G, Lane HA (2008) Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data. J Clin Oncol 26: 1596-1602
38. Vahid B, Marik PE (2008) Pulmonary complications of novel antineoplastic agents for solid tumors. Chest 133: 528-538
39. Vanderweele DJ, Rudin CM (2005) Akt-mTOR signaling mediates resistance to antimicrotubule chemotherapeutic agents. Proc Am Assoc Cancer Res 46: 775. Abstract 3293
40. Yamamoto N, Tsurutani J, Yoshimura N, Asai G, Moriyama A, Nakagawa K, Kudoh S, Takada M, Minato Y, Fukuoka M (2006) Phase II study of weekly paclitaxel for relapsed and refractory small cell lung cancer. Anticancer Res 26: 777-781
41. Yeh KH, Lu YS, Hsu CH, Lin JF, Hsu C, Kuo SH, Li SJ, Cheng AL (2005) Phase II study of weekly paclitaxel and 24-hour infusion of high-dose 5-fluorouracil and leucovorin in the treatment of recurrent or metastatic gastric cancer. Oncology 69: 88-95
42. Yu K, Lucas J, Zhu T, Cai P, Tsao R, Gong Y, Li F, Chaudhary I, Desai P, Ruppen M, Fawzi M, Gibbons J, Ayral-Kaloustian S, Skotnicki J, Mansour T, Zask A (2005) PWT-458, a novel pegylated-17-hydroxywortmannin, inhibits phosphatidylinositol 3-kinase signaling and suppresses growth of solid tumors. Cancer Biol Ther 4: 538-545
43. Yusuf RZ, Duan DE, Lamendola RT, Penson RT, Seiden MV (2003) Paclitaxel resistance: molecular mechanisms and pharmacologic manipulation. Curr Cancer Drug Targets 3: 1-19
44. Zhou X, Tan M, Stone Hawthorne V, Klos KS, Lan KH, Yang Y, Yang W, Smith TL, Shi D, Yu D (2004) Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers. Clin Cancer Res 10: 6779-6788